Markets:

Overview

News

Currencies

International

Treasuries

BeOne Medicines Ltd. - American Depositary Shares (NQ:ONC)

351.71 +0.44 (+0.13%)

Streaming Delayed Price Updated: 10:14 AM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeOne Medicines Ltd. - American Depositary Shares

< Previous 1 2 3 4 Next >

BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26

February 11, 2026

From BeOne Medicines Ltd.

Via Business Wire

3 Stocks to Buy in February ↗

February 02, 2026

These three stocks appear to be poised for strong performances in 2026.

Via The Motley Fool

Topics Artificial Intelligence

BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan ↗

January 21, 2026

Via Chartmill

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

January 13, 2026

From BeOne Medicines Ltd.

Via Business Wire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Where BeOne Medicines Stands With Analysts ↗

October 08, 2025

Via Benzinga

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA

January 06, 2026

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 23, 2025

From BeOne Medicines Ltd.

Via Business Wire

Analyst Expectations For BeOne Medicines's Future ↗

September 18, 2025

Via Benzinga

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

December 18, 2025

From BeOne Medicines Ltd.

Via Business Wire

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

December 08, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk Features ↗

December 07, 2025

BeOne Medicines Ltd. (NASDAQ:ONC, HKEX: 06160, SSE: 688235)), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating...

Via Benzinga

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

December 07, 2025

From BeOne Medicines Ltd.

Via Business Wire

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Via Investor's Business Daily

Topics Economy Government

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

November 26, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

November 20, 2025

From BeOne Medicines Ltd.

Via Business Wire

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans ↗

November 17, 2025

Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.

Via Benzinga

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

November 17, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

November 06, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines to Present at Upcoming Investor Conferences

October 28, 2025

From BeOne Medicines Ltd.

Via Business Wire

Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally ↗

October 27, 2025

Investor Exits $5.5 Million Perpetua Resources Stake Amid Stock's 150% Rally

Via The Motley Fool

Topics Regulatory Compliance

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6

October 22, 2025

From BeOne Medicines Ltd.

Via Business Wire

What's Going On With Summit Therapeutics Stock On Monday? ↗

October 20, 2025

Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.

Via Benzinga

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

October 20, 2025

From BeOne Medicines Ltd.

Via Business Wire

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

October 13, 2025

From BeOne Medicines Ltd.

Via Business Wire

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order ↗

September 10, 2025

Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs.

Via Investor's Business Daily

Topics Government

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 10, 2025

Via Benzinga

Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio? ↗

September 07, 2025

These ten large-cap stocks were top performers last week. Are they a part of your portfolio?

Via Benzinga

Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

September 02, 2025

Via Benzinga

Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket ↗

September 02, 2025

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.